Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL30330386 | 1.00 | GPR3 (0.43) | GPR3KCNH2ACHENSD2NR2F2 | |
| SCHEMBL29251765 | 0.85 | HDAC8 (0.40) | ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL4469432 | 0.82 | GPR3 (0.43) | GPR3KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL29114404 | 0.81 | GPR3 (0.42) | GPR3KCNH2ACHENSD2NR2F2 | |
| Trifluoromethanesulfonic Acid SCHEMBL4476327 | 0.81 | GPR3 (0.42) | GPR3KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL320422 | 0.81 | HDAC8 (0.62) | GPR3KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL31105615 | 0.81 | HDAC8 (0.62) | GPR3KCNH2ACHE | |
| Toluene SCHEMBL11059058 | 0.80 | LMNA (0.41) | ACHE | |
| SCHEMBL8002510 | 0.80 | NPSR1 (0.43) | KCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL6432764 | 0.79 | KCNH2 (0.51) | GPR3KCNH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215713-A1 | Method of producing a crosslinked coating in the manufacture of integrated circuits | KING INDUSTRIES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20030118916-A1 | Heteroaromatic compounds having two-photon absorption activity | PAGANI GIORGIO (IT) | 2003-06-26 | — | — | US | disclosed |
| EP-1268467-A1 | HETEROAROMATIC COMPOUNDS HAVING TWO-PHOTON ABSORPTION ACTIVITY | Universita' Degli Studi Di Milano - Bicocca (IT) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070735-A1 | HETEROAROMATIC COMPOUNDS HAVING TWO-PHOTON ABSORPTION ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118916-A1 | Heteroaromatic compounds having two-photon absorption activity | NPC1L1, ABCG2, ARNT | GPR3 2255/4885KCNH2 1564/4885ACHE 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.